HomeCompareSLRN vs VICI

SLRN vs VICI: Dividend Comparison 2026

SLRN yields 88.11% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRN wins by $1.38M in total portfolio value
10 years
SLRN
SLRN
● Live price
88.11%
Share price
$2.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.37M
Annual income
$731,873.50
Full SLRN calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — SLRN vs VICI

📍 SLRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRNVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRN + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRN pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRN
Annual income on $10K today (after 15% tax)
$7,488.99/yr
After 10yr DRIP, annual income (after tax)
$622,092.48/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, SLRN beats the other by $92,320.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRN + VICI for your $10,000?

SLRN: 50%VICI: 50%
100% VICI50/50100% SLRN
Portfolio after 10yr
$1.68M
Annual income
$677,567.41/yr
Blended yield
40.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

SLRN
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Price Target
$10.50
+362.6% upside vs current
Range: $6.00 — $15.00
Altman Z
1.6
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRN buys
0
VICI buys
0
No recent congressional trades found for SLRN or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRNVICI
Forward yield88.11%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$2.37M$988.8K
Annual income after 10y$731,873.50$623,261.32
Total dividends collected$2.08M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$10.50$31.60

Year-by-year: SLRN vs VICI ($10,000, DRIP)

YearSLRN PortfolioSLRN Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$19,511$8,810.57$11,368$948.43+$8.1KSLRN
2$36,942$16,065.36$13,339$1,493.16+$23.6KSLRN
3$67,956$28,428.44$16,326$2,426.21+$51.6KSLRN
4$121,587$48,874.33$21,123$4,112.15+$100.5KSLRN
5$211,824$81,725.42$29,379$7,368.23+$182.4KSLRN
6$359,715$133,063.84$44,804$14,191.64+$314.9KSLRN
7$596,079$211,183.71$76,658$29,972.12+$519.4KSLRN
8$964,860$327,055.60$150,894$71,015.81+$814.0KSLRN
9$1,527,165$494,764.27$350,814$193,582.47+$1.18MSLRN
10$2,365,940$731,873.50$988,809$623,261.32+$1.38MSLRN

SLRN vs VICI: Complete Analysis 2026

SLRNStock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Full SLRN Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this SLRN vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRN vs SCHDSLRN vs JEPISLRN vs OSLRN vs KOSLRN vs MAINSLRN vs NNNSLRN vs EPRTSLRN vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.